Based on these considerations, we investigated the prognostic significance of serum IL-6 in patients with advanced CSCC undergoing cemiplimab treatment; serum IL-6 levels assessed at baseline and after treatment with cemiplimab were correlated with oncological outcomes in a retrospective study. Here, IL6 is linked to skin squamous cell carcinoma.